Author: Dino Mustafić

September 18, 2024 Off

Breas and ovarian cancer newly linked to thousands of gene variants

By Dino Mustafić

Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold. They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.   

June 18, 2024 Off

Cresset gets SOC 2 compliance

By Dino Mustafić

Cresset, an innovative provider of integrated in silico solutions for drug discovery, has completed its SOC 2Type 1 audit, achieving compliance with the leading industry standards for customer data security.

June 12, 2024 Off

Clasado in deal with Prochin for Bimuno GOS prebiotic in China

By Dino Mustafić

Clasado Biosciences has signed a new exclusive distribution agreement with Shanghai Prochin, a division of health ingredient specialist, Alliance Nutrition Group, which will see galactooligosaccharide ingredient Bimuno GOS made available to health and nutrition formulators in China, marking another exciting step in the commercial growth of Bimuno GOS.